SP differentiation assay for evaluation of CSC enrichment in TOV21G and SKOV3. A & B. Quantification of percent SP fraction in demonstrated enrichment of SP fraction in MP (top panel) and SP (middle panel) fractions but not in NSP (lower panel) fractions after TNFα or cisplatin treatment compared their untreated counterpart. Represented percentage SP fraction was obtained from three independent biological replicates. (TIFF 240 kb
Figure S3. p53 and p21 inhibition reduces and enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to...
Figure S1. Dose-dependent response to carboplatin was tested in SK-OV-3GFP control cells and compare...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Endogenous abundance of subpopulations from differentiation states and subsequent to short-term cisp...
In vivo limiting dilution assays of sorted MDA-MB-231 and MDA-MB-453 breast cancer cells using surfa...
Applied strategy to determine cell cycle phases and cell cycle phase-specific H2AX phosphorylation l...
Activation of WNT-signalling may contribute to survival of UCCs upon long-term cisplatin treatment. ...
Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...
CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. Original flow cytometry data for abun...
Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. Representative...
Figure S1. Analysis of Cisplatin effect on healthy donors CD4+ T cells in vitro. CD4+ T cells were i...
Figure S4. Upregulation of H3K27me3 levels sensitizes OS to cisplatin. Colony formation ability of O...
Figure S3. p53 and p21 inhibition reduces and enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to...
Figure S1. Dose-dependent response to carboplatin was tested in SK-OV-3GFP control cells and compare...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Endogenous abundance of subpopulations from differentiation states and subsequent to short-term cisp...
In vivo limiting dilution assays of sorted MDA-MB-231 and MDA-MB-453 breast cancer cells using surfa...
Applied strategy to determine cell cycle phases and cell cycle phase-specific H2AX phosphorylation l...
Activation of WNT-signalling may contribute to survival of UCCs upon long-term cisplatin treatment. ...
Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...
CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. Original flow cytometry data for abun...
Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. Representative...
Figure S1. Analysis of Cisplatin effect on healthy donors CD4+ T cells in vitro. CD4+ T cells were i...
Figure S4. Upregulation of H3K27me3 levels sensitizes OS to cisplatin. Colony formation ability of O...
Figure S3. p53 and p21 inhibition reduces and enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to...
Figure S1. Dose-dependent response to carboplatin was tested in SK-OV-3GFP control cells and compare...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...